🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Delta, Walgreens, BlackRock, Domino's Rise Premarket; Applied Materials Drops

Published 2022/10/13, 14:24
© Reuters.
AMAT
-
BIIB
-
KSS
-
WBA
-
DAL
-
BLK
-
IXIC
-
DPZ
-
BLAK34
-
A1MT34
-
DCT
-
VSCO
-

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Thursday, October 13th. Please refresh for updates.

  • Delta Air Lines (NYSE:DAL) stock rose 4.4% after the carrier reported record revenue in the third quarter, adding that it expects travel demand to remain robust despite growing risks of an economic recession.

  • Walgreens Boots (NASDAQ:WBA) stock rose 3.9% after the drugstore chain beat quarterly expectations, helped by gains from administering COVID-19 vaccines to cushion the impact of losses from low prescription volumes and over-the-counter sales of health and wellness products.

  • Kohl's (NYSE:KSS) stock rose 2.4% after the Wall Street Journal reported that hedge fund Macellum, an activist investor, is seeking to replace board members.
  • BlackRock (NYSE:BLK) stock rose 1.9% after the world's largest asset manager posted a smaller-than-expected drop in quarterly profit as strong demand for exchange-traded funds and other low-risk products cushioned the hit to fee income from a global market rout.
  • Domino’s Pizza (NYSE:DPZ) stock rose 9.4% after the fast food chain beat quarterly U.S. same-store sales estimates, as heavy discounts helped boost demand for its products.

  • Victoria's Secret (NYSE:VSCO) stock rose 4.6% after the lingerie retailer said it expected third-quarter earnings to be towards the high end of its guidance.

  • Applied Materials (NASDAQ:AMAT) stock fell 1.3% after the semiconductor-equipment manufacturer warned that its fourth-quarter revenue and earnings would miss estimates.

  • Duck Creek (NASDAQ:DCT) stock soared 10.8% after the insurance-technology company’s fourth-quarter earnings beat expectations, helped by improved deal activity.

  • Biogen (NASDAQ:BIIB) stock rose 2.7% after Stifel upgraded its stance on the biotech to ‘buy’ from ‘hold’, saying its Alzheimer drug could be more competitive than its peers.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.